To further investigate the anti-tumor effects of depleting p300 from tumors, we established SMARCB1-proficient H460 cells and SMARCB1-deficient JMU-RTK-2 cells by doxycycline-induced knockdown of EP300. We confirmed that doxycycline decreased expression of p300 by JMU-RTK-2 shEP300 and H460 shEP300 cells, but not by JMU-RTK-2 shNT and H460 shNT cells (Supplementary Fig. 7j, k). Here, EP300 is linked to neoplasm.